# A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs

Study · id `cardio:ct-nct03078478` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03078478](<https://clinicaltrials.gov/study/NCT03078478>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03078478

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1609 participants.

## Technical summary

Registry record NCT03078478. Randomized; no masking; primary purpose treatment. Start 2017-03-13 (actual); primary completion 2019-02-13 (actual). Results posted on 2020-03-12.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1609 participants (enrolled count; ClinicalTrials.gov record NCT03078478, source copy `cardio:ctgov-nct03078478-2022-01-11`, retrieved 2026-10-26)
- Started: 2017-03-13 (actual) (ClinicalTrials.gov record NCT03078478, source copy `cardio:ctgov-nct03078478-2022-01-11`, retrieved 2026-10-26)
- Primary completion: 2019-02-13 (actual) (ClinicalTrials.gov record NCT03078478, source copy `cardio:ctgov-nct03078478-2022-01-11`, retrieved 2026-10-26)
- Completion: 2019-03-04 (actual) (ClinicalTrials.gov record NCT03078478, source copy `cardio:ctgov-nct03078478-2022-01-11`, retrieved 2026-10-26)
- Results first posted: 2020-03-12 (ClinicalTrials.gov record NCT03078478, source copy `cardio:ctgov-nct03078478-2022-01-11`, retrieved 2026-10-26)
- Countries: United States; Canada; Denmark; Estonia; Germany; Greece; Hungary; Norway; Poland; Puerto Rico; Romania; Serbia (ClinicalTrials.gov record NCT03078478, source copy `cardio:ctgov-nct03078478-2022-01-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03078478-2022-01-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs
- Acronym: CONCLUDE
- Condition: Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Insulin degludec
- Intervention (Drug): Insulin glargine
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial (`cardio:pubmed-31984443`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial (`cardio:pubmed-32306247`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: ac59717c52c460e29e813f3022512d1094c56123647349661fa89adba0fe3e97
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
